𝕊𝕪𝕞𝕡𝕠𝕤𝕚𝕦𝕞 𝕕𝕖 𝔸𝕣𝕚𝕤𝕖𝕤 ℕ𝕖𝕥𝕨𝕠𝕣𝕜 𝕒̀ 𝔻𝕒𝕣 𝔼𝕤 𝕊𝕒𝕝𝕒𝕞

𝚄𝚗𝚎 𝚎́𝚚𝚞𝚒𝚙𝚎 𝚍𝚞 𝙲𝚁𝚂𝙽, 𝚌𝚘𝚗𝚍𝚞𝚒𝚝𝚎 𝚙𝚊𝚛 𝚜𝚘𝚗 𝚍𝚒𝚛𝚎𝚌𝚝𝚎𝚞𝚛 𝙳𝚛 𝙰𝚕𝚒 𝚂𝙸𝙴, 𝚙𝚊𝚛𝚝𝚒𝚌𝚒𝚙𝚎 𝚊𝚞 𝟻𝚎̀ 𝚜𝚢𝚖𝚙𝚘𝚜𝚒𝚞𝚖 𝚜𝚌𝚒𝚎𝚗𝚝𝚒𝚏𝚒𝚚𝚞𝚎 𝚍𝚞 𝚛𝚎́𝚜𝚎𝚊𝚞 𝙰𝚁𝙸𝚂𝙴, 𝚚𝚞𝚒 𝚌𝚘𝚖𝚖𝚎𝚗𝚌𝚎 𝚌𝚎 𝚓𝚘𝚞𝚛 𝟷𝟿 𝚓𝚊𝚗𝚟𝚒𝚎𝚛 𝚊̀ 𝙳𝚊𝚛 𝙴𝚜 𝚂𝚊𝚕𝚊𝚖, 𝚊𝚞𝚡 𝚌𝚘̂𝚝𝚎́𝚜 𝚍’𝚊𝚞𝚝𝚛𝚎𝚜 𝚙𝚊𝚛𝚝𝚎𝚗𝚊𝚒𝚛𝚎𝚜 𝚍𝚞 𝚛𝚎́𝚜𝚎𝚊𝚞 𝙰𝚁𝙸𝚂𝙴. 𝙾𝚋𝚓𝚎𝚌𝚝𝚒𝚏 𝚍𝚎 𝚌𝚎𝚝𝚝𝚎 𝚛𝚎𝚗𝚌𝚘𝚗𝚝𝚛𝚎 𝚜𝚌𝚒𝚎𝚗𝚝𝚒𝚏𝚒𝚚𝚞𝚎 est 𝚍𝚎 𝚝𝚛𝚊𝚗𝚜𝚏𝚘𝚛𝚖𝚎𝚛 𝚕𝚊 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚜𝚞𝚛 𝚕𝚊 𝚜𝚊𝚗𝚝𝚎́ 𝚎𝚝 𝚕𝚊 𝚗𝚞𝚝𝚛𝚒𝚝𝚒𝚘𝚗 𝚍𝚎𝚜 𝚊𝚍𝚘𝚕𝚎𝚜𝚌𝚎𝚗𝚝𝚜 𝚎𝚗 𝚙𝚘𝚕𝚒𝚝𝚒𝚚𝚞𝚎𝚜 𝚌𝚘𝚗𝚌𝚛𝚎̀𝚝𝚎𝚜 𝚎𝚗 𝙰𝚏𝚛𝚒𝚚𝚞𝚎 𝚜𝚞𝚋𝚜𝚊𝚑𝚊𝚛𝚒𝚎𝚗𝚗𝚎

Qᴜ’ᴇsᴛ–ᴄᴇ ǫᴜᴇ ʟᴇ ʀᴇsᴇᴀᴜ ARISE

𝙰𝚁𝙸𝚂𝙴 𝚎𝚜𝚝 𝚞𝚗 𝚛𝚎́𝚜𝚎𝚊𝚞 𝚍’𝚊𝚌𝚝𝚒𝚟𝚒𝚝𝚎́𝚜 𝚌𝚘𝚕𝚕𝚊𝚋𝚘𝚛𝚊𝚝𝚒𝚟𝚎𝚜 𝚍’𝚎́𝚍𝚞𝚌𝚊𝚝𝚒𝚘𝚗 𝚎𝚝 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚎𝚗 𝙰𝚏𝚛𝚒𝚚𝚞𝚎 𝚌𝚛𝚎́𝚎́ 𝚙𝚊𝚛 𝚕𝚊 𝙷𝚊𝚛𝚟𝚊𝚛𝚍 𝚃. 𝙷. 𝙲𝚑𝚊𝚗 𝚂𝚌𝚑𝚘𝚘𝚕 𝚘𝚏 𝙿𝚞𝚋𝚕𝚒𝚌 𝙷𝚎𝚊𝚕𝚝𝚑 (𝙷𝚂𝙿𝙷) 𝚎𝚗 𝚙𝚊𝚛𝚝𝚎𝚗𝚊𝚛𝚒𝚊𝚝 𝚊𝚟𝚎𝚌 𝚕’𝙰𝚌𝚊𝚍𝚎́𝚖𝚒𝚎 𝚊𝚏𝚛𝚒𝚌𝚊𝚒𝚗𝚎 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚙𝚞𝚋𝚕𝚒𝚚𝚞𝚎 (𝙰𝙰𝙿𝙷) 𝚎𝚝 𝚍𝚎𝚜 𝚒𝚗𝚜𝚝𝚒𝚝𝚞𝚝𝚒𝚘𝚗𝚜/𝚘𝚛𝚐𝚊𝚗𝚒𝚜𝚊𝚝𝚒𝚘𝚗𝚜 𝚍𝚎 𝚙𝚛𝚎𝚖𝚒𝚎𝚛 𝚙𝚕𝚊𝚗 𝚍𝚊𝚗𝚜 𝚝𝚘𝚞𝚝𝚎 𝚕𝚊 𝚛𝚎́𝚐𝚒𝚘𝚗 𝚊𝚏𝚛𝚒𝚌𝚊𝚒𝚗𝚎. 𝙼𝚒𝚜𝚎 𝚎𝚗 𝚙𝚕𝚊𝚌𝚎 𝚎𝚗 𝚓𝚞𝚒𝚗 𝟸0𝟷𝟺, 𝚕𝚘𝚛𝚜 𝚍’𝚞𝚗𝚎 𝚛𝚎́𝚞𝚗𝚒𝚘𝚗 𝚏𝚘𝚗𝚍𝚊𝚝𝚛𝚒𝚌𝚎 𝚝𝚎𝚗𝚞𝚎 𝚊̀ 𝙱𝚘𝚜𝚝𝚘𝚗, 𝙼𝙰, 𝚊𝚟𝚎𝚌 𝚝𝚘𝚞𝚜 𝚕𝚎𝚜 𝚙𝚊𝚛𝚝𝚎𝚗𝚊𝚒𝚛𝚎𝚜 𝚍𝚎𝚜 𝚎́𝚝𝚊𝚋𝚕𝚒𝚜𝚜𝚎𝚖𝚎𝚗𝚝𝚜 𝚍’𝚎𝚗𝚜𝚎𝚒𝚐𝚗𝚎𝚖𝚎𝚗𝚝 𝚎𝚝 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚍𝚎 𝚜𝚎𝚙𝚝 𝚙𝚊𝚢𝚜 𝚊𝚏𝚛𝚒𝚌𝚊𝚒𝚗𝚜, 𝚊̀ 𝚜𝚊𝚟𝚘𝚒𝚛 𝚕𝚎 𝙱𝚘𝚝𝚜𝚠𝚊𝚗𝚊, 𝚕’𝙴́𝚝𝚑𝚒𝚘𝚙𝚒𝚎, 𝚕𝚎 𝙶𝚑𝚊𝚗𝚊, 𝚕𝚎 𝙽𝚒𝚐𝚎𝚛𝚒𝚊, 𝚕’𝙰𝚏𝚛𝚒𝚚𝚞𝚎 𝚍𝚞 𝚂𝚞𝚍, 𝚕𝚊 𝚃𝚊𝚗𝚣𝚊𝚗𝚒𝚎 𝚎𝚝 𝚕’𝙾𝚞𝚐𝚊𝚗𝚍𝚊, 𝚙𝚘𝚞𝚛 𝚍𝚒𝚜𝚌𝚞𝚝𝚎𝚛 𝚍𝚎 𝚕’𝚊𝚟𝚊𝚗𝚌𝚎́𝚎 𝚍𝚎𝚜 𝚊𝚌𝚝𝚒𝚟𝚒𝚝𝚎́𝚜 𝚍’𝚎𝚗𝚜𝚎𝚒𝚐𝚗𝚎𝚖𝚎𝚗𝚝 𝚎𝚝 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚌𝚘𝚘𝚛𝚍𝚘𝚗𝚗𝚎́𝚎𝚜 𝚎𝚝 𝚌𝚘𝚕𝚕𝚊𝚋𝚘𝚛𝚊𝚝𝚒𝚟𝚎𝚜 𝚊𝚏𝚒𝚗 𝚍𝚎 𝚌𝚘𝚖𝚋𝚕𝚎𝚛 𝚕𝚎𝚜 𝚕𝚊𝚌𝚞𝚗𝚎𝚜 𝚌𝚛𝚒𝚝𝚒𝚚𝚞𝚎𝚜 𝚎𝚗 𝚖𝚊𝚝𝚒𝚎̀𝚛𝚎 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚍𝚎 𝚕𝚊 𝚙𝚘𝚙𝚞𝚕𝚊𝚝𝚒𝚘𝚗.

𝙲𝚎𝚝𝚝𝚎 𝚛𝚎𝚗𝚌𝚘𝚗𝚝𝚛𝚎 𝚊 𝚎́𝚝𝚎́ 𝚕’𝚘𝚌𝚌𝚊𝚜𝚒𝚘𝚗 𝚍𝚎 𝚌𝚛𝚎́𝚎𝚛 𝚞𝚗 𝚛𝚎́𝚜𝚎𝚊𝚞 𝚚𝚞𝚒 𝚜’𝚊𝚙𝚙𝚞𝚒𝚎 𝚜𝚞𝚛 𝚕𝚎𝚜 𝚗𝚘𝚖𝚋𝚛𝚎𝚞𝚜𝚎𝚜 𝚊𝚌𝚝𝚒𝚟𝚒𝚝𝚎́𝚜 𝚍𝚎 𝚏𝚘𝚛𝚖𝚊𝚝𝚒𝚘𝚗 𝚎𝚝 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚎𝚗 𝚌𝚘𝚞𝚛𝚜 𝚍𝚊𝚗𝚜 𝚕𝚎𝚜 𝚒𝚗𝚜𝚝𝚒𝚝𝚞𝚝𝚒𝚘𝚗𝚜 𝚙𝚊𝚛𝚝𝚒𝚌𝚒𝚙𝚊𝚗𝚝𝚎𝚜 – 𝚕𝚎 𝚁𝚎́𝚜𝚎𝚊𝚞 𝚊𝚏𝚛𝚒𝚌𝚊𝚒𝚗 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎, 𝚍𝚎 𝚜𝚌𝚒𝚎𝚗𝚌𝚎 𝚍𝚎 𝚕𝚊 𝚖𝚒𝚜𝚎 𝚎𝚗 œ𝚞𝚟𝚛𝚎 𝚎𝚝 𝚍’𝚎́𝚍𝚞𝚌𝚊𝚝𝚒𝚘𝚗 (𝚁𝚎́𝚜𝚎𝚊𝚞 𝙰𝚁𝙸𝚂𝙴). 𝙿𝚊𝚛𝚖𝚒 𝚕𝚎𝚜 𝚒𝚗𝚜𝚝𝚒𝚝𝚞𝚝𝚒𝚘𝚗𝚜 𝚖𝚎𝚖𝚋𝚛𝚎𝚜 𝚍𝚞 𝚛𝚎́𝚜𝚎𝚊𝚞 𝙰𝚁𝙸𝚂𝙴 𝚏𝚒𝚐𝚞𝚛𝚎𝚗𝚝 𝚕’𝙰𝚌𝚊𝚍𝚎́𝚖𝚒𝚎 𝚊𝚏𝚛𝚒𝚌𝚊𝚒𝚗𝚎 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚙𝚞𝚋𝚕𝚒𝚚𝚞𝚎 𝚎𝚗 𝚃𝚊𝚗𝚣𝚊𝚗𝚒𝚎, 𝚕𝚊 𝙵𝚘𝚗𝚍𝚊𝚝𝚒𝚘𝚗 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚍𝚎 𝚕’𝚄𝚗𝚒𝚟𝚎𝚛𝚜𝚒𝚝𝚎́ 𝚍’𝙸𝚋𝚊𝚍𝚊𝚗 𝚊𝚞 𝙽𝚒𝚐𝚎𝚛𝚒𝚊, 𝚕’𝚄𝚗𝚒𝚟𝚎𝚛𝚜𝚒𝚝𝚎́ 𝚍𝚎 𝙺𝚠𝚊𝚉𝚞𝚕𝚞-𝙽𝚊𝚝𝚊𝚕 𝚎𝚗 𝙰𝚏𝚛𝚒𝚚𝚞𝚎 𝚍𝚞 𝚂𝚞𝚍, 𝚕’𝙸𝚗𝚜𝚝𝚒𝚝𝚞𝚝 𝚗𝚊𝚝𝚒𝚘𝚗𝚊𝚕 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚙𝚞𝚋𝚕𝚒𝚚𝚞𝚎 – 𝙲𝚎𝚗𝚝𝚛𝚎 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚎𝚗 𝚜𝚊𝚗𝚝𝚎́ 𝚍𝚎 𝙽𝚘𝚞𝚗𝚊 𝚊𝚞 𝙱𝚞𝚛𝚔𝚒𝚗𝚊 𝙵𝚊𝚜𝚘, 𝚕’𝚄𝚗𝚒𝚟𝚎𝚛𝚜𝚒𝚝𝚎́ 𝚍𝚎 𝙼𝚊𝚔𝚎𝚛𝚎𝚛𝚎 – 𝙴́𝚌𝚘𝚕𝚎 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚙𝚞𝚋𝚕𝚒𝚚𝚞𝚎 𝚎𝚗 𝙾𝚞𝚐𝚊𝚗𝚍𝚊, 𝚕’𝙸𝚗𝚜𝚝𝚒𝚝𝚞𝚝 𝚌𝚘𝚗𝚝𝚒𝚗𝚎𝚗𝚝𝚊𝚕 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚙𝚞𝚋𝚕𝚒𝚚𝚞𝚎 𝚍’𝙰𝚍𝚍𝚒𝚜 𝚎𝚗 𝙴́𝚝𝚑𝚒𝚘𝚙𝚒𝚎, 𝚕𝚎 𝙲𝚎𝚗𝚝𝚛𝚎 𝚍𝚎 𝚛𝚎𝚌𝚑𝚎𝚛𝚌𝚑𝚎 𝚎𝚗 𝚜𝚊𝚗𝚝𝚎́ 𝚍𝚎 𝙳𝚘𝚍𝚘𝚠𝚊 𝚊𝚞 𝙶𝚑𝚊𝚗𝚊 𝚎𝚝 𝚕’𝙴́𝚌𝚘𝚕𝚎 𝚍𝚎 𝚜𝚊𝚗𝚝𝚎́ 𝚙𝚞𝚋𝚕𝚒𝚚𝚞𝚎 𝚍𝚎 𝚕’𝚄𝚗𝚒𝚟𝚎𝚛𝚜𝚒𝚝𝚎́ 𝚍𝚞 𝙶𝚑𝚊𝚗𝚊, 𝚎́𝚐𝚊𝚕𝚎𝚖𝚎𝚗𝚝 𝚊𝚞 𝙶𝚑𝚊𝚗𝚊

Panélistes

SCRP@CRSN 2024

Aᴢɪᴛʜʀᴏᴍʏᴄɪɴ ᴅᴜʀɪɴɢ Rᴏᴜᴛɪɴᴇ Wᴇʟʟ-Iɴғᴀɴᴛ Vɪsɪᴛs ᴛᴏ Pʀᴇᴠᴇɴᴛ Dᴇᴀᴛʜ

Aᴢɪᴛʜʀᴏᴍʏᴄɪɴ ᴅᴜʀɪɴɢ Rᴏᴜᴛɪɴᴇ Wᴇʟʟ-Iɴғᴀɴᴛ Vɪsɪᴛs ᴛᴏ Pʀᴇᴠᴇɴᴛ Dᴇᴀᴛʜ

  • Ali Sié, M.D., Ph.D., Mamadou Ouattara, M.D.,Mamadou Bountogo, M.D.,Valentin Boudo, M.S.,Thierry Ouedraogo, Ph.D.,Guillaume Compaoré, M.D.,Clarisse Dah, M.D.,Cheik Bagagnan, M.S.,
  • Elodie Lebas, R.N.,Huiyu Hu, M.S.P.H.,Jessica Rice, M.P.H.,Travis C. Porco, Ph.D., M.P.H.,Benjamin F. Arnold, Ph.D., M.P.H.,homas M. Lietman, M.D.,and Catherine E. Oldenburg, Sc.D., M.P.H.& all

𝐴𝑏𝑠𝑡𝑟𝑎𝑐𝑡

𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑

𝑀𝑎𝑠𝑠 𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 𝑡𝑜 𝑐ℎ𝑖𝑙𝑑𝑟𝑒𝑛 1 𝑡𝑜 59 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑎𝑔𝑒 ℎ𝑎𝑠 𝑏𝑒𝑒𝑛 𝑠ℎ𝑜𝑤𝑛 𝑡𝑜 𝑟𝑒𝑑𝑢𝑐𝑒 𝑐ℎ𝑖𝑙𝑑ℎ𝑜𝑜𝑑 𝑎𝑙𝑙-𝑐𝑎𝑢𝑠𝑒 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑖𝑛 𝑠𝑜𝑚𝑒 𝑠𝑢𝑏-𝑆𝑎ℎ𝑎𝑟𝑎𝑛 𝐴𝑓𝑟𝑖𝑐𝑎𝑛 𝑟𝑒𝑔𝑖𝑜𝑛𝑠, 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑙𝑎𝑟𝑔𝑒𝑠𝑡 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑠𝑒𝑒𝑛 𝑎𝑚𝑜𝑛𝑔 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑦𝑜𝑢𝑛𝑔𝑒𝑟 𝑡ℎ𝑎𝑛 12 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑎𝑔𝑒. 𝑊ℎ𝑒𝑡ℎ𝑒𝑟 𝑡ℎ𝑒 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 𝑎𝑡 𝑟𝑜𝑢𝑡𝑖𝑛𝑒 ℎ𝑒𝑎𝑙𝑡ℎ 𝑐𝑎𝑟𝑒 𝑣𝑖𝑠𝑖𝑡𝑠 𝑓𝑜𝑟 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑤𝑜𝑢𝑙𝑑 𝑏𝑒 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑖𝑛 𝑝𝑟𝑒𝑣𝑒𝑛𝑡𝑖𝑛𝑔 𝑑𝑒𝑎𝑡ℎ 𝑖𝑠 𝑢𝑛𝑐𝑙𝑒𝑎𝑟.

 𝑀𝑒𝑡ℎ𝑜𝑑𝑠

𝑊𝑒 𝑐𝑜𝑛𝑑𝑢𝑐𝑡𝑒𝑑 𝑎 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑧𝑒𝑑, 𝑝𝑙𝑎𝑐𝑒𝑏𝑜-𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑙𝑒𝑑 𝑡𝑟𝑖𝑎𝑙 𝑜𝑓 𝑎 𝑠𝑖𝑛𝑔𝑙𝑒 𝑑𝑜𝑠𝑒 𝑜𝑓 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 (20 𝑚𝑔 𝑝𝑒𝑟 𝑘𝑖𝑙𝑜𝑔𝑟𝑎𝑚 𝑜𝑓 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡) 𝑎𝑠 𝑐𝑜𝑚𝑝𝑎𝑟𝑒𝑑 𝑤𝑖𝑡ℎ 𝑝𝑙𝑎𝑐𝑒𝑏𝑜, 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑖𝑛𝑓𝑎𝑛𝑐𝑦 (5 𝑡𝑜 12 𝑤𝑒𝑒𝑘𝑠 𝑜𝑓 𝑎𝑔𝑒). 𝑇ℎ𝑒 𝑝𝑟𝑖𝑚𝑎𝑟𝑦 𝑒𝑛𝑑 𝑝𝑜𝑖𝑛𝑡 𝑤𝑎𝑠 𝑑𝑒𝑎𝑡ℎ 𝑏𝑒𝑓𝑜𝑟𝑒 6 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑎𝑔𝑒. 𝐼𝑛𝑓𝑎𝑛𝑡𝑠 𝑤𝑒𝑟𝑒 𝑟𝑒𝑐𝑟𝑢𝑖𝑡𝑒𝑑 𝑎𝑡 𝑟𝑜𝑢𝑡𝑖𝑛𝑒 𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑜𝑟 𝑜𝑡ℎ𝑒𝑟 𝑤𝑒𝑙𝑙-𝑐ℎ𝑖𝑙𝑑 𝑣𝑖𝑠𝑖𝑡𝑠 𝑖𝑛 𝑐𝑙𝑖𝑛𝑖𝑐𝑠 𝑎𝑛𝑑 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑐𝑜𝑚𝑚𝑢𝑛𝑖𝑡𝑦 𝑜𝑢𝑡𝑟𝑒𝑎𝑐ℎ 𝑖𝑛 𝑡ℎ𝑟𝑒𝑒 𝑟𝑒𝑔𝑖𝑜𝑛𝑠 𝑜𝑓 𝐵𝑢𝑟𝑘𝑖𝑛𝑎 𝐹𝑎𝑠𝑜. 𝑉𝑖𝑡𝑎𝑙 𝑠𝑡𝑎𝑡𝑢𝑠 𝑤𝑎𝑠 𝑎𝑠𝑠𝑒𝑠𝑠𝑒𝑑 𝑎𝑡 6 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑎𝑔𝑒.

𝑅𝑒𝑠𝑢𝑙𝑡𝑠

𝑂𝑓 𝑡ℎ𝑒 32,877 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑒𝑛𝑟𝑜𝑙𝑙𝑒𝑑 𝑓𝑟𝑜𝑚 𝑆𝑒𝑝𝑡𝑒𝑚𝑏𝑒𝑟 2019 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑂𝑐𝑡𝑜𝑏𝑒𝑟 2022, 𝑎 𝑡𝑜𝑡𝑎𝑙 𝑜𝑓 16,416 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑤𝑒𝑟𝑒 𝑟𝑎𝑛𝑑𝑜𝑚𝑙𝑦 𝑎𝑠𝑠𝑖𝑔𝑛𝑒𝑑 𝑡𝑜 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 𝑎𝑛𝑑 16,461 𝑡𝑜 𝑝𝑙𝑎𝑐𝑒𝑏𝑜. 𝐸𝑖𝑔ℎ𝑡𝑦-𝑡𝑤𝑜 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 𝑔𝑟𝑜𝑢𝑝 𝑎𝑛𝑑 75 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑙𝑎𝑐𝑒𝑏𝑜 𝑔𝑟𝑜𝑢𝑝 𝑑𝑖𝑒𝑑 𝑏𝑒𝑓𝑜𝑟𝑒 6 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑎𝑔𝑒 (ℎ𝑎𝑧𝑎𝑟𝑑 𝑟𝑎𝑡𝑖𝑜, 1.09; 95% 𝑐𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙 [𝐶𝐼], 0.80 𝑡𝑜 1.49; 𝑃=0.58); 𝑡ℎ𝑒 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑤𝑎𝑠 0.04 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑝𝑜𝑖𝑛𝑡𝑠 (95% 𝐶𝐼, −0.10 𝑡𝑜 0.21). 𝑇ℎ𝑒𝑟𝑒 𝑤𝑎𝑠 𝑛𝑜 𝑒𝑣𝑖𝑑𝑒𝑛𝑐𝑒 𝑜𝑓 𝑎𝑛 𝑒𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 𝑜𝑛 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑖𝑛 𝑎𝑛𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑒𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑒𝑑 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑠, 𝑖𝑛𝑐𝑙𝑢𝑑𝑖𝑛𝑔 𝑠𝑢𝑏𝑔𝑟𝑜𝑢𝑝𝑠 𝑑𝑒𝑓𝑖𝑛𝑒𝑑 𝑎𝑐𝑐𝑜𝑟𝑑𝑖𝑛𝑔 𝑡𝑜 𝑎𝑔𝑒, 𝑠𝑒𝑥, 𝑎𝑛𝑑 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑎𝑛𝑑 𝑛𝑜 𝑒𝑣𝑖𝑑𝑒𝑛𝑐𝑒 𝑜𝑓 𝑎 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑡𝑤𝑜 𝑡𝑟𝑖𝑎𝑙 𝑔𝑟𝑜𝑢𝑝𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑜𝑓 𝑎𝑑𝑣𝑒𝑟𝑠𝑒 𝑒𝑣𝑒𝑛𝑡𝑠.

𝐶𝑜𝑛𝑐𝑙𝑢𝑠𝑖𝑜𝑛𝑠

𝐼𝑛 𝑡ℎ𝑖𝑠 𝑡𝑟𝑖𝑎𝑙 𝑐𝑜𝑛𝑑𝑢𝑐𝑡𝑒𝑑 𝑖𝑛 𝐵𝑢𝑟𝑘𝑖𝑛𝑎 𝐹𝑎𝑠𝑜, 𝑤𝑒 𝑓𝑜𝑢𝑛𝑑 𝑡ℎ𝑎𝑡 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑧𝑖𝑡ℎ𝑟𝑜𝑚𝑦𝑐𝑖𝑛 𝑡𝑜 𝑖𝑛𝑓𝑎𝑛𝑡𝑠 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑡ℎ𝑒 𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔 ℎ𝑒𝑎𝑙𝑡ℎ 𝑐𝑎𝑟𝑒 𝑠𝑦𝑠𝑡𝑒𝑚 𝑑𝑖𝑑 𝑛𝑜𝑡 𝑝𝑟𝑒𝑣𝑒𝑛𝑡 𝑑𝑒𝑎𝑡ℎ. (𝐹𝑢𝑛𝑑𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝐵𝑖𝑙𝑙 𝑎𝑛𝑑 𝑀𝑒𝑙𝑖𝑛𝑑𝑎 𝐺𝑎𝑡𝑒𝑠 𝐹𝑜𝑢𝑛𝑑𝑎𝑡𝑖𝑜𝑛; 𝐶𝐻𝐴𝑇 𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙𝑇𝑟𝑖𝑎𝑙𝑠.𝑔𝑜𝑣 𝑛𝑢𝑚𝑏𝑒𝑟, 𝑁𝐶𝑇03676764. 𝑜𝑝𝑒𝑛𝑠 𝑖𝑛 𝑛𝑒𝑤 𝑡𝑎𝑏.)

Lire la suite

https://www.nejm.org/doi/full/10.1056/NEJMoa2309495

 

Pʀᴏғɪʟ ᴅᴇs ᴜᴛɪʟɪsᴀᴛʀɪᴄᴇs ᴇᴛ ғᴀᴄᴛᴇᴜʀs ᴀssᴏᴄɪᴇ́s ᴀ̀ ʟᴀ sᴀᴛɪsғᴀᴄᴛɪᴏɴ ᴅᴇs ᴄʟɪᴇɴᴛᴇs ᴅᴇ ʟᴀ ǫᴜᴀʟɪᴛᴇ́ ᴅᴇs SAA

Pʀᴏғɪʟ ᴅᴇs ᴜᴛɪʟɪsᴀᴛʀɪᴄᴇs ᴇᴛ ғᴀᴄᴛᴇᴜʀs ᴀssᴏᴄɪᴇ́s ᴀ̀ ʟᴀ sᴀᴛɪsғᴀᴄᴛɪᴏɴ ᴅᴇs ᴄʟɪᴇɴᴛᴇs ᴅᴇ ʟᴀ ǫᴜᴀʟɪᴛᴇ́ ᴅᴇs sᴏɪɴs ᴀᴘʀᴇ̀s ᴀᴠᴏʀᴛᴇᴍᴇɴᴛ ᴀᴜ Bᴜʀᴋɪɴᴀ Fᴀsᴏ: ᴇ́ᴛᴜᴅᴇ ᴛʀᴀɴsᴠᴇʀsᴀʟᴇ ᴍᴇɴᴇ́ᴇ ᴅᴀɴs sɪx ʀᴇ́ɢɪᴏɴs

Rᴇ́sᴜᴍᴇ́

Rᴇ́sᴜᴍᴇ́

Mᴀʟɢʀᴇ́ ʟᴀ ᴅᴇ́ᴘᴇ́ɴᴀʟɪsᴀᴛɪᴏɴ ᴅᴇ ʟ’ᴀᴠᴏʀᴛᴇᴍᴇɴᴛ ᴇᴛ ʟᴀ ɢʀᴀᴛᴜɪᴛᴇ́ ᴅᴇs sᴏɪɴs ᴀᴘʀᴇ̀s ᴀᴠᴏʀᴛᴇᴍᴇɴᴛ (SAA), ʟᴇs ꜰᴇᴍᴍᴇs Bᴜʀᴋɪɴᴀʙᴇ̀ ᴠɪᴠᴇɴᴛ ᴅᴇs ʀᴇʟᴀᴛɪᴏɴs ᴅɪꜰꜰɪᴄɪʟᴇs ᴀᴠᴇᴄ ʟᴇs sᴏɪɢɴᴀɴᴛs. Cᴇᴛᴛᴇ ᴇ́ᴛᴜᴅᴇ ᴠɪsᴇ ᴀ̀ ᴅᴇ́ᴛᴇʀᴍɪɴᴇʀ ʟᴇ ᴘʀᴏꜰɪʟ ᴅᴇs ꜰᴇᴍᴍᴇs ʀᴇᴄᴇᴠᴀɴᴛ ᴅᴇs SAA, ʟᴇᴜʀ ᴘᴇʀᴄᴇᴘᴛɪᴏɴ ᴅᴇ ʟᴀ ǫᴜᴀʟɪᴛᴇ́ ᴅᴇs SAA ᴇᴛ sᴇs ᴅᴇ́ᴛᴇʀᴍɪɴᴀɴᴛs ᴅᴀɴs ᴅᴇs sᴛʀᴜᴄᴛᴜʀᴇs sᴀɴɪᴛᴀɪʀᴇs ᴘᴜʙʟɪǫᴜᴇs ᴇᴛ ᴄᴏɴꜰᴇssɪᴏɴɴᴇʟʟᴇs ᴅᴜ ᴘᴀʏs. Uɴᴇ ᴇɴǫᴜᴇ̂ᴛᴇ ǫᴜᴀɴᴛɪᴛᴀᴛɪᴠᴇ ᴀ ᴇ́ᴛᴇ́ ᴍᴇɴᴇ́ᴇ ᴀᴜᴘʀᴇ̀s ᴅᴇ 2174 ꜰᴇᴍᴍᴇs ᴠᴜᴇs ᴘᴏᴜʀ ᴅᴇs SAA ᴇᴛ ʀᴇᴄʀᴜᴛᴇ́ᴇs ᴅᴇ ꜰᴀᴄ̧ᴏɴ ᴇxʜᴀᴜsᴛɪᴠᴇ ᴅᴇ 2018 ᴀ̀ 2020. Uɴ ǫᴜᴇsᴛɪᴏɴɴᴀɪʀᴇ sᴛʀᴜᴄᴛᴜʀᴇ́ ᴀ ᴇ́ᴛᴇ́ ᴀᴅᴍɪɴɪsᴛʀᴇ́ ᴀ̀ ʟᴀ sᴏʀᴛɪᴇ ᴅᴇs sᴏɪɴs. Uɴᴇ ᴀɴᴀʟʏsᴇ ᴜɴɪ-, ʙɪ- ᴇᴛ ᴍᴜʟᴛɪᴠᴀʀɪᴇ́ᴇ ᴀ ᴇ́ᴛᴇ́ ꜰᴀɪᴛᴇ. Lᴀ ᴍᴀᴊᴏʀɪᴛᴇ́ ᴅᴇs ᴄʟɪᴇɴᴛᴇs ᴅᴇ SAA ᴠɪᴠᴀɪᴛ ᴇɴ ᴍɪʟɪᴇᴜ ʀᴜʀᴀʟ (55%), ᴀᴠᴀɪᴛ 25 ᴀɴs ᴇᴛ ᴘʟᴜs (60%), ᴠɪᴠᴀɪᴛ ᴇɴ ᴄᴏᴜᴘʟᴇ (87%) ᴇᴛ ᴇ́ᴛᴀɪᴛ sᴀɴs-ᴇᴍᴘʟᴏɪ (59%). Lᴀ ɢʀᴏssᴇssᴇ ᴇ́ᴛᴀɪᴛ ɴᴏɴ ᴅᴇ́sɪʀᴇ́ᴇ ᴄʜᴇᴢ 17% ᴅᴇs ꜰᴇᴍᴍᴇs ᴇᴛ 4% ᴅ’ᴇɴᴛʀᴇ ᴇʟʟᴇs sᴏᴜʜᴀɪᴛᴀɪᴇɴᴛ ᴀᴠᴏʀᴛᴇʀ. Lᴀ sᴀᴛɪsꜰᴀᴄᴛɪᴏɴ ɢʟᴏʙᴀʟᴇ ᴅᴇ ʟᴀ ǫᴜᴀʟɪᴛᴇ́ ᴅᴇs SAA ᴇ́ᴛᴀɪᴛ ᴅᴇ 84%. Dᴀɴs ʟ’ᴀɴᴀʟʏsᴇ ᴍᴜʟᴛɪᴠᴀʀɪᴇ́ᴇ, sᴇs ᴅᴇ́ᴛᴇʀᴍɪɴᴀɴᴛs ᴇ́ᴛᴀɪᴇɴᴛ ʟᴀ ʀᴇ́sɪᴅᴇɴᴄᴇ ᴇɴ ᴍɪʟɪᴇᴜ ʀᴜʀᴀʟ (OR = 1.80 [1.38; 2.34]), ᴜɴ ɴɪᴠᴇᴀᴜ sᴄᴏʟᴀɪʀᴇ ᴘʀɪᴍᴀɪʀᴇ (OR = 1.48 [1.06; 2.07]) ᴏᴜ sᴇᴄᴏɴᴅᴀɪʀᴇ (OR = 1.95 [1.38; 2.74]), ᴇᴛ ᴀᴠᴏɪʀ ᴇᴜ ᴀᴜ ᴍᴏɪɴs ᴜɴ ᴇɴꜰᴀɴᴛ (OR = 1.43 [1.02; 2.00]). Lᴇs ꜰᴀᴄᴛᴇᴜʀs ᴀssᴏᴄɪᴇ́s ᴀ̀ ᴜɴᴇ ꜰᴀɪʙʟᴇ sᴀᴛɪsꜰᴀᴄᴛɪᴏɴ ᴅᴇs SAA ᴇ́ᴛᴀɪᴇɴᴛ ᴜɴᴇ ɢʀᴏssᴇssᴇ ɴᴏɴ ᴅᴇ́sɪʀᴇ́ᴇ (OR = 0.64 [0.46; 0.89]) ᴏᴜ ᴀᴠᴏɪʀ sᴏᴜʜᴀɪᴛᴇ́ ᴀᴠᴏʀᴛᴇʀ (OR = 0.09 [0.05; 0.16]). Lᴇ ɴɪᴠᴇᴀᴜ ᴅᴇ sᴀᴛɪsꜰᴀᴄᴛɪᴏɴ ɢʟᴏʙᴀʟᴇ ᴇsᴛ ᴀᴄᴄᴇᴘᴛᴀʙʟᴇ ᴍᴀɪs ꜰᴀɪʙʟᴇ ᴄʜᴇᴢ ʟᴇs ᴄʟɪᴇɴᴛᴇs ᴀʏᴀɴᴛ sᴏᴜʜᴀɪᴛᴇ́ ᴀᴠᴏʀᴛᴇʀ. Iʟ ᴇsᴛ ꜰᴏɴᴅᴀᴍᴇɴᴛᴀʟ ᴅ’ᴏʀɢᴀɴɪsᴇʀ ᴜɴ ᴘʀᴏɢʀᴀᴍᴍᴇ ᴅᴇ ꜰᴏʀᴍᴀᴛɪᴏɴ ᴅᴇs ᴘʀᴏꜰᴇssɪᴏɴɴᴇʟs ᴅᴇs SAA sᴜʀ ʟᴀ ᴄᴏᴍᴍᴜɴɪᴄᴀᴛɪᴏɴ, ʟᴀ ʀᴇʟᴀᴛɪᴏɴ ɪɴᴛᴇʀᴘᴇʀsᴏɴɴᴇʟʟᴇ ᴇᴛ ʟ’ᴇᴍᴘᴀᴛʜɪᴇ ᴘᴇɴᴅᴀɴᴛ ʟᴇs sᴏɪɴs ᴅᴇ sᴀɴᴛᴇ́.

Lire la suite..

https://www.tandfonline.com/doi/full/10.1080/26410397.2023.2272483